GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

BOLT · Jun 30, 2026

Bolt Biotherapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 4[email protected]

Inspectable configuration

State dimensions

Filing0001193125-26-344597General Corporate

Operating cash generation0thOwn-history percentile · N=16

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-130800.00% · OPTIONAL · VALID

Revenue growth0thOwn-history percentile · N=12

Evidence method

Yoy · gp.fundamentals.revenue

-99.72% · CORE · VALID

Operating margin0thOwn-history percentile · N=16

Evidence method

Level · gp.fundamentals.operating_margin

-167480.00% · CORE · VALID

R&D intensity100thOwn-history percentile · N=16

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

102980.00% · OPTIONAL · VALID

SBC intensity100thOwn-history percentile · N=16

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

11040.00% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History13 statesSelf-history eligible

Jun 30, 20230/6 normalizedLevel 3 Sep 30, 20230/6 normalizedLevel 3 Dec 31, 20230/6 normalizedLevel 3 Mar 31, 20240/6 normalizedLevel 3 Jun 30, 20245/6 normalizedLevel 3 Sep 30, 20245/6 normalizedLevel 3 Dec 31, 20245/6 normalizedLevel 3 Mar 31, 20254/5 normalizedLevel 3 Jun 30, 20255/5 normalizedLevel 3 Sep 30, 20255/5 normalizedLevel 3 Dec 31, 20256/6 normalizedLevel 3 Mar 31, 20265/5 normalizedLevel 3 Jun 30, 20265/5 normalizedLevel 4

Period transition

What moved in the state?

Cash Generation Decreased

Previous: -30857.69%
Current: -130800.00%
Delta: -99942.31%

Growth Decreased

Previous: -97.87%
Current: -99.72%
Delta: -1.85%

Profitability Decreased

Previous: -29234.62%
Current: -167480.00%
Delta: -138245.38%

R And D Intensity Increased

Previous: 18573.08%
Current: 102980.00%
Delta: 84406.92%

Sbc Intensity Increased

Previous: 2096.15%
Current: 11040.00%
Delta: 8943.85%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Mar 31, 2026

Similarity: 100%
Compared: 5 dimensions
Coverage: 100%

Growth 0.0 · Profitability 0.0 · Sbc Intensity 0.0 · Cash Generation 0.0 · R And D Intensity 0.0

Jun 30, 2024

Similarity: 77%
Compared: 4 dimensions
Coverage: 80%

Profitability 0.0 · Sbc Intensity 0.0 · Cash Generation 37.5 · R And D Intensity 25.0

Mar 31, 2025

Similarity: 30%
Compared: 4 dimensions
Coverage: 80%

Profitability 63.6 · Sbc Intensity 90.9 · Cash Generation 45.5 · R And D Intensity 72.7

Sep 30, 2025

Similarity: 5%
Compared: 5 dimensions
Coverage: 100%

Growth 88.9 · Profitability 92.3 · Sbc Intensity 100.0 · Cash Generation 92.3 · R And D Intensity 100.0

Research Graph

Related governed research

Analogous To · BOLT state analogue 2 →Analogous To · BOLT state analogue 1 →Compared To · Pharmaceutical Preparations peers →Analogous To · BOLT state analogue 3 →Analogous To · BOLT state analogue 4 →Transitioned To · BOLT Fundamental State →Transitioned To · BOLT CASH_GENERATION_DECREASED →Transitioned To · BOLT GROWTH_DECREASED →Transitioned To · BOLT PROFITABILITY_DECREASED →Transitioned To · BOLT R_AND_D_INTENSITY_INCREASED →Transitioned To · BOLT SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.